Oculis (OCS)
Develops investigational therapies for neuro-ophthalmology and dry eye disease.
Something off on this page? Send us feedback.
Develops investigational ophthalmic and neuro-ophthalmic therapies, with development focused on Privosegtor and Licaminlimab. Its programs build on OPTIREACH eye-drop formulation research and licensed assets.
Investigational eye-care pipeline includes Privosegtor for neuro-ophthalmic programs and Licaminlimab for ocular inflammation and dry eye disease. Both are registrational programs following the 2026 change in development focus.
OPTIREACH formulation research was designed to enable eye drops to reach the back of the eye. The portfolio also reflects licenses for Licaminlimab and Privosegtor from Novartis and Accure Therapeutics.
Headquartered in Switzerland, operations span the United States and Iceland. All named programs remain investigational, and the company will not pursue an FDA filing for OCS-01 in diabetic macular edema after its Phase 3 trials missed their primary endpoint.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 1, 2026 | Robert W. Baird | Target | Target: $37 | Target: $38 |
| Jun 1, 2026 | Guggenheim | Reiterate | Rating: —Target: $75 | Target: $45 |
| Jun 1, 2026 | Needham | Reiterate | Rating: —Target: — | Target: $38 |
| Jun 1, 2026 | H.C. Wainwright | Target | Target: $47 | Target: $26 |
| May 20, 2026 | Guggenheim | Target | Target: — | Target: $75 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.7K · Total debt $3.1M · Total assets $303.4M · Shareholders' equity $265.8M
- Revenue
- $0
- Operating income
- −$28.6M
- Net income
- −$12.1M
Reported in CHF, converted at the latest exchange rate
No dividends on record.
| Institutions | ≥ 38.64% | 23.22M ADS | |
|---|---|---|---|
| 62 holders · as of Jun 30, 2026 | |||
| Other | ≤ 61.36% | 36.87M ADS | |
| remainder | |||
60.09M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Institutional filings for OCSAW (4% of the company) are not on file here, so the institutional figure is a floor.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Eqt Fund Management S.A R.L.Institution | 11.57% | 6.95M ADS | as of Jun 30, 2026 |
Abrdn PLCInstitution | 3.59% | 2.16M ADS | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 3.40% | 2.04M ADS | as of Jun 30, 2026 |
Pivotal Bioventure Partners Investment Advisor LLCInstitution | 2.51% | 1.51M ADS | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 1.64% | 987,204 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Bausch + Lomb
FDA-approved Xiidra and Miebo anchor a scaled dry-eye portfolio
- Viatris
Commercial Tyrvaya and a planned Phase 3 program in dry eye
- Aldeyra Therapeutics
NDA-stage reproxalap remains a contingent dry-eye rival
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Oculis | $10.31 | −3.73% | $612.3M | — | — | 2,073.2 | +16.8% |
| Bausch + Lomb | $17.04 | −1.65% | $6.19B | — | 17.1 | 1.2 | +9.1% |
| Viatris | $17.07 | −0.64% | $20.01B | — | 6.7 | 1.4 | +4.9% |
| Aldeyra Therapeutics | $1.35 | −3.23% | $84.1M | — | — | — | — |
| Median | — | 11.9 | 1.3 | +7.0% |